Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

Fida Biosystems ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.2% 1.2%   Bankruptcy risk   5.4% 5.9% 1.5% 1.1% 2.2% 3.7% 5.7% 5.3%   Credit score (0-100)   43 40 77 84 65 50 40 42   Credit rating   BBB BBB A A BBB BBB BBB BBB   Credit limit (kDKK)   0.0 0.0 76.2 965.3 0.8 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   870 1,119 7,807 8,908 10,929 8,694 0.0 0.0   EBITDA   181 -650 1,786 2,697 -937 -8,980 0.0 0.0   EBIT   124 -1,145 640 1,846 -4,054 -13,683 0.0 0.0   Pre-tax profit (PTP)   80.0 -1,185.9 578.4 1,669.7 -3,530.1 -13,926.7 0.0 0.0   Net earnings   62.3 -933.2 833.1 1,926.5 -2,582.8 -12,960.9 0.0 0.0   Pre-tax profit without non-rec. items   80.0 -1,186 578 1,670 -3,530 -13,927 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 196 385 744 963 660 0.0 0.0   Shareholders equity total   -84.7 3,407 9,490 16,666 27,083 21,123 10,770 10,770   Interest-bearing liabilities   400 390 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   3,043 12,474 21,073 29,718 41,760 38,793 10,770 10,770   Net Debt   305 -7,524 -7,126 -4,748 -7,067 -5,112 -10,669 -10,669     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   870 1,119 7,807 8,908 10,929 8,694 0.0 0.0   Gross profit growth   1,205.0% 28.6% 597.7% 14.1% 22.7% -20.5% -100.0% 0.0%   Employees   1 2 7 9 17 19 0 0   Employee growth %   0.0% 100.0% 250.0% 28.6% 88.9% 11.8% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   3,043 12,474 21,073 29,718 41,760 38,793 10,770 10,770   Balance sheet change%   160.2% 309.9% 68.9% 41.0% 40.5% -7.1% -72.2% 0.0%   Added value   180.6 -650.2 1,785.9 2,696.8 -3,203.4 -8,979.9 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   1,885 55 3,884 8,339 -2,788 -8,847 -13,765 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   1.0 -1.0 1.0 2.0 -1.0 -2.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   14.3% -102.3% 8.2% 20.7% -37.1% -157.4% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   5.6% -14.7% 3.8% 7.3% -9.8% -33.7% 0.0% 0.0%   ROI %   31.1% -53.7% 9.4% 13.9% -15.8% -56.3% 0.0% 0.0%   ROE %   3.0% -28.9% 12.9% 14.7% -11.8% -53.8% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   -2.7% 27.3% 45.0% 56.1% 64.9% 54.4% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   169.2% 1,157.3% -399.0% -176.0% 754.2% 56.9% 0.0% 0.0%   Gearing %   -472.5% 11.4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   11.1% 10.8% 31.6% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   0.0 1.0 1.0 0.7 1.4 1.6 0.0 0.0   Current Ratio   0.0 1.0 1.1 0.9 1.6 2.0 0.0 0.0   Cash and cash equivalent   94.5 7,914.4 7,126.5 4,747.5 7,067.5 5,112.0 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   -2,995.0 -82.6 1,207.8 -957.1 9,187.8 12,245.8 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   181 -325 255 300 -188 -473 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   181 -325 255 300 -55 -473 0 0   EBIT / employee   124 -573 91 205 -238 -720 0 0   Net earnings / employee   62 -467 119 214 -152 -682 0 0